1. Introduction {#sec1}
===============

In Japan, the incidence of cardiovascular events has been increasing on account of the westernization of lifestyle and increases in the prevalence of overweight and metabolic syndrome \[[@B1], [@B2]\]. Recently, endothelial dysfunction has been recognized as a crucial pathogenesis in the early stage of arteriosclerosis \[[@B3], [@B4]\]. Traditional risk factors such as hypertension, dyslipidemia, and hyperglycemia are associated with endothelial dysfunction \[[@B4]\], and endothelial dysfunction itself is also reported to be an independent risk factor in the development of cardiovascular events \[[@B5]\]. Endothelial dysfunction is reversible, and its improvement can prevent the development of arteriosclerosis.

Flow-mediated dilatation (FMD) has been used for the measurement of endothelial function, and by this method the change of forearm vascular diameter is evaluated by ultrasonic apparatus \[[@B6]\]. On the other hand, reactive hyperemia peripheral arterial tonometry (RH-PAT), a noninvasive apparatus developed recently, allows easier measurement compared to FMD \[[@B7], [@B8]\]. It requires a less-operator-dependent technique, and the influence of sympathetic nervous activity in RH-PAT is less than that in FMD. Therefore, it makes possible the comparison of measured values from different devices.

Keishibukuryogan (KBG; Guizhi-Fuling-Wan) is a traditional Japanese (Kampo) formula used to prevent the development of atherosclerosis. In recent years, we reported the protective effects of KBG on endothelial function in cholesterol-fed rabbits and spontaneously diabetic rats \[[@B9], [@B10]\]. Further, we revealed that KBG actually inhibits the progression of atherosclerosis in cholesterol-fed rabbits \[[@B11], [@B12]\]. However, it has not been assessed whether KBG prevents the progression of atherosclerosis clinically in human subjects, and long-term study is not easy to conduct. Therefore, this time we set out to evaluate the effects of KBG on endothelial function using RH-PAT in patients with metabolic syndrome-related factors by a controlled clinical trial with crossover design.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

The diagnostic criteria for metabolic syndrome adopted in the study were defined by the Examination Committee for Criteria of metabolic syndrome in Japan, that is, (1) waist circumference ≥85 cm in men and ≥90 cm in women; in addition 2 or more of the following 3 components: (2) triglyceride (TG) ≥ 150 mg/dL and/or high-density lipoprotein (HDL) cholesterol \< 40 mg/dL, (3) systolic blood pressure (SBP) ≥ 130 mmHg and/or diastolic blood pressure (DBP) ≥ 85 mmHg, and (4) fasting plasma glucose (FPG) ≥ 110 mg/dL \[[@B13]\]. We recruited patients aged 40--80 years who were consulting the Department of Japanese Oriental Medicine, Toyama University Hospital, for treatment of various diseases or symptoms, and having 1 or more components of the above diagnostic criteria between June 2008 and August 2011. Patients with serious liver or kidney disease, infectious disease, malignancy, previous stroke or myocardial infarction, or other diseases considered to possibly disturb the implementation of this trial, were excluded from enrollment.

2.2. KBG {#sec2.2}
--------

KBG consists of 5 dried herbal medicines: Cinnamomi Cortex, Paeoniae Radix, Moutan Cortex, Persicae Semen, and Hoelen. These herbal powders were mixed with boiled honey at the ratio shown in [Table 1](#tab1){ref-type="table"} and rolled up into balls (2 g each). All these herbal medicines and honey were purchased from Uchida Wakanyaku Co. (Tokyo, Japan).

2.3. Study Design {#sec2.3}
-----------------

The study was a controlled clinical trial with crossover design consisting of a 4-week KBG-treatment period and a 4-week control period. The patients were randomly assigned into group A (KBG-treatment, period I; control, period II) or group B (control, period I; KBG-treatment, period II). The Framingham heart study using the FMD technique revealed that flow-mediated vascular dilatation is influenced by season or temperature and is highest in summer and lowest in winter \[[@B14]\]. Therefore, we set both period I and period II in the same season, and the interval between the 2 periods at about one year. Patients were evaluated at most 4 times (test 1, beginning of period I; test 2, end of period I; test 3, beginning of period II; test 4, end of period II). KBG (6 g per day) was administered three times a day after meals in addition to their usual prescribed drugs for 4 weeks in period I in group A or period II in group B. These concomitant drugs had not been changed for at least 3 months before the beginning point of and during period I and period II ([Figure 1](#fig1){ref-type="fig"}). This study was an open-label study, as it was impossible to prepare a suitable placebo due to the unique flavor and taste of KBG.

The study design was approved by the Ethics Committee, University of Toyama. All patients provided written informed consent in accordance with the ethical guidelines set forth in the 1975 Declaration of Helsinki.

2.4. RH-PAT {#sec2.4}
-----------

Endothelial function was evaluated by Endo-PAT2000 (Itamar Medical, Caesarea, Israel). The principle of RH-PAT has been described previously \[[@B7], [@B8], [@B15]\]. Briefly, a blood pressure cuff was placed on one upper arm, while the contralateral arm served as control. PAT probes were placed on one finger (finger II or III) of each hand (same finger on both hands). After a 5-minute equilibration period, the cuff was inflated to the higher of either 60 mmHg above systolic pressure or 200 mmHg for 5 min and then deflated to induce reactive hyperemia. PAT signals were recorded electronically in both fingers. During these procedures, the subject was requested to remain quiet and still, and the room temperature was controlled at 21--24°C. The RH-PAT data were analyzed by computer with Endo-PAT2000 software version 3.1.2 in an operator-independent manner. The PH-PAT index reflects the extent of reactive hyperemia and was calculated as the ratio of the average amplitude of PAT signal over 1 min starting 1.5 min after cuff deflation (hyperemic finger, A; control finger, C) divided by the average amplitude of the PAT signal of a 2.5-minute duration before cuff inflation (baseline, hyperemic finger, B; control finger, D). Then, the reactive hyperthermia index (RHI) was obtained from this equation: RHI = (A/B)/(C/D) × baseline correction factor. Recently, the natural logarithmic scaled RHI (L_RHI) has often been used instead of RHI \[[@B4], [@B15], [@B16]\], and we also used it in this study ([Figure 2](#fig2){ref-type="fig"}).

2.5. Physical Findings and Laboratory Data {#sec2.5}
------------------------------------------

Immediately before the examination of RH-PAT, patients were evaluated for physical findings, such as height (HT), body weight (BW), waist circumference, and SBP and DBP after 5-minute rest at supine position. Body mass index (BMI) was also calculated (BMI = BW (kg)/HT (m)^2^).

Blood was collected from the cubital vein after overnight fasting immediately after the RH-PAT examination, and partially separated serum was frozen at −80°C immediately and stored until assay. Routine clinical laboratory data, such as TG, HDL-cholesterol, low-density lipoprotein (LDL) cholesterol, FPG, immunoreactive insulin (IRI), creatinine, and high-sensitive C-reactive protein (hs-CRP), were measured by standard laboratory techniques in our hospital. Homeostasis model assessment as an index of insulin resistance (HOMA-IR) was performed for the evaluation of insulin resistance: \[HOMA-IR = IRI (*μ*U/mL) × FPG (mg/dL)/405\] \[[@B17]\]. Nonesterified fatty acid (NEFA; free fatty acid) was measured by enzyme method at Mitsubishi Chemical Medience Co., Tokyo, Japan. We measured malondialdehyde (MDA), a marker of oxidative stress, by thiobarbituric acid reactive substance (TBARS) assay kit (OXI-TEK TBARS Assay Kit; ZeptoMetrix Co., New York, USA), and soluble vascular cell adhesion molecule 1 (sVCAM-1) by Human sVCAM-1 Quantikine ELISA Kit (R&D Systems Inc., Minneapolis, USA) in our laboratory.

2.6. Statistical Analysis {#sec2.6}
-------------------------

Statistical analysis was performed with JMP 9 (SAS Institute Japan, Tokyo). Data were expressed as mean ± S.E. Either Wilcoxon test or Pearson\'s chi-square test was used for statistical analysis of the patient\'s characteristics. The difference between the data at week 0 and week 4 was analyzed using the Wilcoxon matched-pairs signed-ranks test. Comparison between the change of values in KBG-treatment period and control period was performed by MANOVA test. A value of *P* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Patients {#sec3.1}
-------------

In total, 100 patients were initially enrolled, but 8 were then excluded (6, deviation from inclusion criteria; 2, consent withdrawn), and 92 patients were finally quasi-randomized to group A (*n* = 46) and group B (*n* = 46), and entered into period I ([Figure 1](#fig1){ref-type="fig"}).

In group A, after test 1, 6 patients were excluded \[3, refused intake of KBG; 1, adverse effect (glossalgia); 1, change of concomitant drug; 1, eating before test\], and after the 4-week KBG-treatment period the remaining 40 patients underwent test 2 and completed period I. During the interval of about 1 year between periods I and II, 10 patients dropped out (7, refused to participate; 2, onset of other disease; 1, discontinued hospital visit). The other 30 patients entered into period II and underwent test 3. After that, 3 patients were excluded (1, onset of infectious disease; 2, change of concomitant drug), and after the 4-week control period, the remaining 27 patients underwent test 4 and completed period II.

In group B, after test 1, 5 patients were excluded (3, refused to participate; 1, onset of infectious disease; 1, eating before test), and after the 4-week control period, the remaining 41 patients underwent test 2 and completed period I. During the interval between periods I and II, 12 patients dropped out (7, refused to participate; 1, onset of other disease; 4, discontinued hospital visit), and the other 29 patients entered into period II and underwent test 3. After that, 7 patients were excluded (2, adverse effects (diarrhea, mouth bitterness); 4, change of concomitant drug; 1, eating before test), and after the 4-week KBG-treatment period, the remaining 22 patients underwent test 4 and completed period II.

3.2. Patient Characteristics {#sec3.2}
----------------------------

The baseline characteristics of the patients who completed all the tests are shown in [Table 2](#tab2){ref-type="table"}. A statistical difference between the 2 groups was seen in male waist circumference, but not in any of the other factors.

3.3. Effects of KBG {#sec3.3}
-------------------

Comparison between various parameters at week 0 and week 4 in both the KBG-treatment period and control period and that of 4-week changes between the KBG-treatment period and control period in patients completing all tests (49 patients in group A + B, 27 in group A plus 22 in group B) are shown in [Table 3](#tab3){ref-type="table"}. The mean value of L_RHI in the KBG-treatment period increased significantly, but not in the control period, and the 4-week changes between KBG-treatment and control periods showed statistical significance. Further, the mean values of NEFA, MDA, and sVCAM-1 in the KBG-treatment period decreased significantly, and 4-week changes of the former 2 parameters between KBG-treatment and control periods were statistically significant.

Separate data of group A ([Table 4](#tab4){ref-type="table"}) and group B ([Table 5](#tab5){ref-type="table"}) are also shown. In group A, the mean value of L_RHI in the KBG-treatment period increased significantly, but not in the control period, and the 4-week changes between the KBG-treatment and control periods showed statistical significance. The mean value of NEFA in the KBG-treatment period decreased significantly, and the 4-week changes between the KBG-treatment and control periods showed statistical significance. Further, the levels of MDA and sVCAM-1 in the KBG-treatment period decreased significantly. Similarly in group B, the mean value of L_RHI in the KBG-treatment period increased significantly. The levels of NEFA and MDA in the KBG-treatment period decreased significantly, and the 4-week changes of MDA levels between the KBG-treatment and control periods showed statistical significance.

4. Discussion {#sec4}
=============

The risk factors of cardiovascular diseases, such as diabetes mellitus, hypertension, and dyslipidemia, often accumulate in the same person and increase the incidence of cardiovascular events synergistically. The concept of metabolic syndrome arose from a global movement to unify such high-risk pathological conditions. In Japan also, clinical diagnostic criteria of metabolic syndrome were announced in 2005 \[[@B13]\]. Endothelial dysfunction is often seen in patients with metabolic syndrome, and it is recognized as a primary pathogenic factor of atherosclerosis \[[@B4], [@B18]\]. Metabolic syndrome is an independent risk factor for cardiovascular events, and if it is combined with endothelial dysfunction, the risk is elevated further \[[@B19]\].

Several methods have been developed to evaluate endothelial function, and they enable us to perform the examination even for outpatients. Evaluation of endothelial function using FMD or PAT is useful for the early detection of arteriosclerosis. The RHI calculated using the PAT signal is applied to a parameter of endothelial function. Endothelial function in the brachial circulation correlates with that in the coronary circulation, and low RHI is useful for identifying a patient with coronary endothelial dysfunction \[[@B7]\]. Thus, PAT is considered to be a useful, noninvasive examination for the prediction of later cardiovascular events \[[@B16]\]. A value of RHI ≤ 1.67 (L_RHI ≤ 0.51) measured by Endo-PAT2000 is considered to be endothelial dysfunction, is determined in the population with a risk for ischemic heart disease, and is recognized as a cut-off value \[[@B20]\]. The relationship between RHI and metabolic syndrome-related components had been reported \[[@B4]\]. A specific characteristic of endothelial function is its reversibility, and it can be a novel therapeutic target. Studies concerning the effect of drug or supplement on endothelial function using RHI have been reported on the basis of its sensitive reaction to treatment \[[@B21], [@B22]\].

In the present study, we evaluated the endothelial function of patients with metabolic syndrome-related factors using RHI by controlled clinical trial with crossover design and revealed that KBG has the potential to improve endothelial function. That is, L_RHI increased significantly in the KBG-treatment period, but not in the control period. It was reported that patients with lower RHI had a higher incidence of cardiovascular events during the followup period \[[@B16]\], and improvement of impaired endothelial function is important for the prevention of the development of arteriosclerosis \[[@B3]\]. Therefore, KBG might be useful for preventing the progression of endothelial dysfunction and arteriosclerosis. All the patients enrolled in this study were free of obvious findings of arteriosclerosis, but endothelial dysfunction (L_RHI ≤ 0.51 at test 1) was seen in 37.0% (34/92) of them. Most of the conventional methods for assessing arteriosclerosis evaluate its advanced stage. Endothelial dysfunction is observed even in the initial and early stages of the progression of atherosclerosis. Therefore, an intervention for endothelial dysfunction by KBG in an as yet latent stage of arteriosclerosis is considered useful for the prevention of eventual cardiovascular events.

We have previously reported that KBG improves microcirculation evaluated by erythrocyte aggregability and deformability in patients with multiple old lacunar infarction \[[@B23], [@B24]\]. In experimental animal models, we have also demonstrated that KBG has protective effects against endothelial dysfunction in cholesterol-fed rabbits and spontaneously diabetic rats \[[@B9], [@B10]\], in addition to its inhibitory effect against plaque formation \[[@B11], [@B12]\]. KBG is composed of 5 herbal medicines: Cinnamomi Cortex, Paeoniae Radix, Moutan Cortex, Persicae Semen, and Hoelen. We have reported that polyphenols of Cinnamomi Cortex and Paeoniae Radix have endothelium-dependent relaxative effects \[[@B25], [@B26]\]. Cinnamaldehyde contained in Cinnamomi Cortex also has endothelium-dependent relaxation effect \[[@B27], [@B28]\]. These effects of KBG and composing herbal medicines are assumed to contribute to the efficacy of KBG on endothelial function.

It is reported that the elevated level of NEFA is related to metabolic syndrome and endothelial dysfunction, and that it is an independent predictive factor for cardiovascular events \[[@B29]\]. In our previous study, KBG decreased the plasma level of NEFA in cholesterol-fed rabbits \[[@B30]\], and in the present clinical trial, NEFA was also decreased. Therefore, KBG seems to have the actual potential to decrease NEFA, and this effect might contribute to the improvement of endothelial function.

In the present study, the levels of MDA decreased. Oxidative stress has been reported to impair endothelial function and accelerate the progression of atherosclerosis. A highly oxidized condition aggravates endothelial dysfunction and depresses nitric oxide production \[[@B31], [@B32]\], and drugs having antioxidant activity possess protective effects against endothelial dysfunction. Previous reports have indicated that each component of the diagnostic criteria of metabolic syndrome is individually related to oxidative stress and endothelial dysfunction \[[@B33]\]. We reported the antioxidative effect of KBG, and this effect is beneficial for the prevention of endothelial dysfunction and arteriosclerosis \[[@B9]--[@B12]\].

As for sVCAM-1, in our previous study dealing with rheumatoid arthritis patients, KBG decreased the plasma levels of sVCAM-1 \[[@B34]\]. VCAM-1 is expressed on the impaired endothelium is regulated by various factors such as oxidative stress and cytokines \[[@B35], [@B36]\] and has been considered to be an important risk factor to the progression of atherosclerosis and cardiovascular events \[[@B37]\]. In the present study, the value of sVCAM-1 was decreased by KBG-treatment in group A. We speculated that the antioxidant effect of KBG might lead to the downregulation of VCAM-1.

From the results of the present study, it is suggested that KBG has the potential to prevent the progression of endothelial dysfunction and arteriosclerosis by its antioxidative effect, and early detection of endothelial dysfunction with PAT and early treatment with KBG might contribute to the prevention of arteriosclerosis.

5. Conclusion {#sec5}
=============

Our present controlled clinical trial with crossover design revealed that KBG improves endothelial function as evaluated by L_RHI in patients with metabolic syndrome-related factors, suggesting that KBG has beneficial effects against the progression of endothelial dysfunction and arteriosclerosis.
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![Flow chart of patients enrolled in the study.](ECAM2012-359282.001){#fig1}

![Representative signals of reactive hyperemia peripheral arterial tonometry (RH-PAT) with (a) normal and (b) low-reactive hyperemic response. Normal response characterized by a distinct increase in the signal amplitude after cuff release compared with baseline.](ECAM2012-359282.002){#fig2}

###### 

Herbal medicines composing KBG and their ratio.

                     Herbal medicine                            Ratio (g)
  ------------------ -------------------------------- --------- -----------
  Cinnamomi Cortex   *Cinnamomum cassia* BLUME        Guizhi    0.2
  Paeoniae Radix     *Paeonia lactiflora* PALLAS      Shaoyao   0.2
  Moutan Cortex      *Paeonia suffruticosa* ANDREWS   Mudanpi   0.2
  Persicae Semen     *Prunus persica* BATSCH          Taoren    0.2
  Hoelen             *Poria cocos* WOLF               Fuling    0.2

KBG: keishibukuryogan.

These 5 herbal powders were mixed with boiled honey (1 g) and rolled up into balls (2 g each).

###### 

Patient characteristics.

                                         Group A (*n* = 27)   Group B (*n* = 22)   *P*-value
  -------------------------------------- -------------------- -------------------- ------------
  Age (year)                             63.5 ± 1.6           62.0 ± 1.7           0.3925^a^
  Sex (male/female)                      11/16                9/13                 0.9905^b^
  Smoking (yes/no)                       2/25                 1/21                 0.6740^b^
  Alcohol intake (yes/no)                12/15                11/11                0.6983^b^
  BMI (kg/m^2^)                          24.1 ± 0.6           22.8 ± 0.6           0.3149^a^
  Waist circumference (cm)                                                         
   Male                                  91.5 ± 3.1           83.0 ± 1.6           0.0435^∗a^
   Female                                81.6 ± 1.7           82.5 ± 2.7           0.9649^a^
  SBP (mmHg)                             126.3 ± 3.2          123.8 ± 2.6          0.7096^a^
  DBP (mmHg)                             76.3 ± 2.5           75.7 ± 2.2           0.5938^a^
  TG (mg/dL)                             129.2 ± 14.6         128.3 ± 14.7         0.6802^a^
  HDL-cholesterol (mg/dL)                65.4 ± 3.8           60.4 ± 3.2           0.2515^a^
  FPG (mg/dL)                            103.7 ± 3.3          101.4 ± 2.6          0.9278^a^
  Central obesity (yes/no)               11/16                7/15                 0.5193^b^
  High blood pressure (yes/no)           16/11                13/9                 0.9905^b^
  Dyslipidemia (yes/no)                  12/15                11/11                0.6983^b^
  Hyperglycemia (yes/no)                 8/19                 7/15                 0.8687^b^
  Concomitant drugs                                                                
   Calcium channel blocker (yes/no)      8/19                 7/15                 0.8687^b^
   ARB or ACE inhibitor (yes/no)         3/24                 4/18                 0.4817^b^
    *α* or *β* blocker (yes/no)          3/24                 1/21                 0.4038^b^
   Statin (yes/no)                       11/16                8/14                 0.7544^b^
   Fibrate (yes/no)                      1/26                 0/22                 0.3618^b^
   Sulfonylurea (yes/no)                 3/24                 1/21                 0.4038^b^
   Thiazolidine analog (yes/no)          3/24                 0/22                 0.1066^b^
    *α*-glucosidase inhibitor (yes/no)   2/25                 1/21                 0.6777^b^
   Antiplatelet drug (yes/no)            1/26                 0/22                 0.3618^b^
  Season test 1 performed                6/14/5/2             9/5/8/0              0.0682^b^
   (Spring/Summer/Fall/Winter)                                                     

BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglyceride; HDL: high-density lipoprotein; FPG: fasting plasma glucose; central obesity, waist circumference ≥ 85 cm (male), ≥90 cm (female); high blood pressure, SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg; dyslipidemia, TG ≥ 150 mg/dL and/or HDL cholesterol \< 40 mg/dL; hyperglycemia, FPG ≥ 110 mg/dL; ARB: angiotensin II receptor blocker; ACE: angiotensin-converting enzyme; Spring: March 21 to June 20; Summer: June 21 to September 21; Fall: September 21 to December 20; Winter: December 21 to March 20.

^a^Comparison between group A and group B by Wilcoxon test.

^b^Comparison between group A and group B by Pearson\'s chi-square test.

Data are expressed as mean ± S.E., \**P* \< 0.05.

###### 

Effects of KBG on various parameters in A + B group (*n* = 49).

                             Period         Week 0         Week 4         *P*-value^a^   *P*-value^b^
  -------------------------- -------------- -------------- -------------- -------------- --------------
  BMI (kg/m^2^)              KBG            23.5 ± 0.4     23.5 ± 0.5     0.3976         0.3034
  Control                    23.5 ± 0.5     23.5 ± 0.5     0.9700                        
  Waist circumference (cm)   KBG            85.0 ± 1.2     85.0 ± 1.2     0.9280         0.9136
  Control                    85.2 ± 1.3     85.3 ± 1.3     0.9462                        
  SBP (mmHg)                 KBG            125.0 ± 2.3    121.0 ± 2.1    0.0321\*       0.2591
  Control                    123.1 ± 1.9    122.0 ± 1.9    0.3629                        
  DBP (mmHg)                 KBG            74.6 ± 1.6     73.9 ± 1.4     0.1297         0.4088
  Control                    73.2 ± 1.4     74.1 ± 1.2     0.5626                        
  L_RHI                      KBG            0.58 ± 0.03    0.70 ± 0.04    0.0003\*\*     0.0034\*\*
  Control                    0.64 ± 0.04    0.60 ± 0.03    0.7279                        
  TG (mg/dL)                 KBG            124.3 ± 8.9    123.2 ± 7.8    0.9453         0.5339
  Control                    125.6 ± 8.9    119.1 ± 6.2    0.6347                        
  HDL-cholesterol (mg/dL)    KBG            62.0 ± 2.6     62.0 ± 2.5     0.6699         0.3016
  Control                    62.6 ± 2.1     61.4 ± 2.0     0.1810                        
  LDL-cholesterol (mg/dL)    KBG            132.7 ± 4.8    133.8 ± 5.0    0.5803         0.1155
  Control                    131.4 ± 4.6    127.7 ± 5.0    0.0435\*                      
  NEFA (*μ*Eq/L)             KBG            532.9 ± 32.9   450.9 ± 26.0   0.0024\*\*     0.0113\*
  Control                    507.6 ± 31.9   529.6 ± 29.0   0.3273                        
  FPG (mg/dL)                KBG            101.0 ± 2.3    101.5 ± 2.8    0.9159         0.2087
  Control                    105.5 ± 3.0    103.1 ± 3.1    0.1297                        
  IRI (*μ*U/mL)              KBG            5.73 ± 0.42    5.47 ± 0.39    0.2609         0.5396
  Control                    6.26 ± 0.52    6.26 ± 0.52    0.9156                        
  HOMA-IR                    KBG            1.46 ± 0.12    1.42 ± 0.12    0.3842         0.8010
  Control                    1.69 ± 0.17    1.68 ± 0.19    0.8639                        
  Creatinine (mg/dL)         KBG            0.71 ± 0.02    0.72 ± 0.03    0.8238         0.6513
  Control                    0.71 ± 0.02    0.71 ± 0.02    1.0000                        
  hs-CRP (mg/dL)             KBG            0.13 ± 0.05    0.13 ± 0.04    0.3721         0.7501
  Control                    0.11 ± 0.03    0.10 ± 0.02    0.3173                        
  MDA (nmol/mL)              KBG            11.8 ± 1.1     9.5 ± 1.0      \<0.0001\*\*   0.0424\*
  Control                    12.9 ± 1.9     12.3 ± 1.9     0.2804                        
  sVCAM-1 (ng/mL)            KBG            723.1 ± 43.4   677.7 ± 40.9   0.0126\*       0.1659
  Control                    724.3 ± 36.0   714.0 ± 36.3   0.8107                        

KBG: keishibukuryogan; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; L_RHI: natural logarithmic scaled reactive hyperemia; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein; NEFA: nonesterified fatty acid; FPG: fasting plasma glucose; IRI: immunoreactive insulin; HOMA-IR: homeostasis model assessment as an index of insulin resistance; hs-CRP: high-sensitive C-reactive protein; MDA: malondialdehyde; sVCAM-1: soluble vascular cell adhesion molecule 1.

^a^Comparison between week 0 and week 4 by Wilcoxon matched-pairs signed-ranks test.

^b^Comparison of 4-week changes between KBG-treatment period and control period by MANOVA test.

Data are expressed as mean ± S.E., \**P* \< 0.05, \*\**P* \< 0.01.

###### 

Effects of KBG on various parameters in group A (*n* = 27).

                             Period         Week 0         Week 4         *P*-value^a^   *P*-value^b^
  -------------------------- -------------- -------------- -------------- -------------- --------------
  BMI (kg/m^2^)              KBG            24.1 ± 0.6     24.2 ± 0.6     0.3362         0.6182
  Control                    24.2 ± 0.7     24.2 ± 0.7     0.5916                        
  Waist circumference (cm)   KBG            85.6 ± 1.8     85.8 ± 2.0     0.6699         0.9871
  Control                    87.2 ± 1.9     87.3 ± 1.9     0.8962                        
  SBP (mmHg)                 KBG            126.3 ± 3.2    125.4 ± 3.2    0.6820         0.9476
  Control                    122.6 ± 2.8    121.5 ± 2.8    0.5591                        
  DBP (mmHg)                 KBG            76.3 ± 2.5     75.9 ± 2.0     0.3790         0.4292
  Control                    71.2 ± 1.8     73.3 ± 1.7     0.3028                        
  L_RHI                      KBG            0.58 ± 0.04    0.70 ± 0.05    0.0231\*       0.0085\*\*
  Control                    0.65 ± 0.05    0.55 ± 0.04    0.1834                        
  TG (mg/dL)                 KBG            129.2 ± 14.6   128.1 ± 12.7   0.7791         0.5937
  Control                    123.4 ± 11.0   116.6 ± 8.9    0.5277                        
  HDL-cholesterol (mg/dL)    KBG            65.4 ± 3.8     66.0 ± 3.6     0.8341         0.6859
  Control                    64.5 ± 2.7     64.5 ± 2.4     0.8432                        
  LDL-cholesterol (mg/dL)    KBG            138.5 ± 5.9    143.1 ± 6.8    0.2268         0.0715
  Control                    130.5 ± 5.3    127.3 ± 5.5    0.1422                        
  NEFA (*μ*Eq/L)             KBG            527.8 ± 49.1   445.4 ± 33.9   0.0306\*       0.0004\*\*
  Control                    440.0 ± 30.3   545.9 ± 42.4   0.0028\*\*                    
  FPG (mg/dL)                KBG            103.7 ± 3.3    105.9 ± 4.6    0.3768         0.2550
  Control                    108.9 ± 5.0    106.6 ± 5.2    0.7477                        
  IRI (*μ*U/mL)              KBG            6.71 ± 0.58    6.05 ± 0.58    0.0593         0.1223
  Control                    6.86 ± 0.78    7.18 ± 0.79    0.5777                        
  HOMA-IR                    KBG            1.73 ± 0.17    1.63 ± 0.19    0.2001         0.3213
  Control                    1.91 ± 0.26    2.00 ± 0.30    0.4815                        
  Creatinine (mg/dL)         KBG            0.70 ± 0.03    0.70 ± 0.03    0.5742         1.0000
  Control                    0.71 ± 0.03    0.71 ± 0.04    0.9734                        
  hs-CRP (mg/dL)             KBG            0.10 ± 0.03    0.10 ± 0.02    0.1962         0.2681
  Control                    0.07 ± 0.01    0.11 ± 0.02    0.0423\*                      
  MDA (nmol/mL)              KBG            10.2 ± 1.5     8.7 ± 1.4      0.0007\*\*     0.5068
  Control                    12.8 ± 2.5     11.9 ± 2.1     0.3444                        
  sVCAM-1 (ng/mL)            KBG            769.5 ± 72.6   708.2 ± 66.3   0.0121\*       0.2791
  Control                    735.8 ± 51.3   711.6 ± 48.3   0.7389                        

KBG: keishibukuryogan; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; L_RHI, natural logarithmic scaled reactive hyperemia; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein; NEFA: nonesterified fatty acid; FPG: fasting plasma glucose; IRI: immunoreactive insulin; HOMA-IR: homeostasis model assessment as an index of insulin resistance; hs-CRP: high-sensitive C-reactive protein; MDA: malondialdehyde; sVCAM-1: soluble vascular cell adhesion molecule 1.

^a^Comparison between week 0 and week 4 by Wilcoxon signed-rank test.

^b^Comparison of 4-week changes between KBG-treatment period and control period by MANOVA test.

Data are expressed as mean ± S.E., \**P* \< 0.05, \*\**P* \< 0.01.

###### 

Effects of KBG on various parameters in group B (*n* = 22).

                             Period         Week 0         Week 4         *P*-value^a^   *P*-value^b^
  -------------------------- -------------- -------------- -------------- -------------- --------------
  BMI (kg/m^2^)              Control        22.8 ± 0.6     22.7 ± 0.6     0.4477         0.3443
  KBG                        22.7 ± 0.6     22.7 ± 0.6     0.7660                        
  Waist circumference (cm)   Control        82.7 ± 1.7     82.8 ± 1.6     0.9129         0.8807
  KBG                        84.1 ± 1.5     84.1 ± 1.3     0.8125                        
  SBP (mmHg)                 Control        123.8 ± 2.6    122.5 ± 2.3    0.4676         0.0808
  KBG                        123.4 ± 3.3    115.5 ± 2.2    0.0037\*\*                    
  DBP (mmHg)                 Control        75.7 ± 2.2     75.2 ± 1.6     0.5524         0.7949
  KBG                        72.5 ± 1.8     71.5 ± 1.9     0.1567                        
  L_RHI                      Control        0.62 ± 0.05    0.66 ± 0.05    0.2870         0.1751
  KBG                        0.56 ± 0.05    0.70 ± 0.05    0.0074\*\*                    
  TG (mg/dL)                 Control        128.3 ± 14.7   122.2 ± 8.6    0.9750         0.7320
  KBG                        118.4 ± 8.4    117.2 ± 7.8    0.9251                        
  HDL-cholesterol (mg/dL)    Control        60.4 ± 3.2     57.7 ± 3.1     0.0718         0.3085
  KBG                        57.8 ± 3.2     57.2 ± 3.3     0.4357                        
  LDL-cholesterol (mg/dL)    Control        132.6 ± 8.0    128.2 ± 9.0    0.1619         0.7604
  KBG                        125.5 ± 7.7    122.5 ± 6.7    0.5393                        
  NEFA (*μ*Eq/L)             Control        590.5 ± 56.6   509.5 ± 39.0   0.1289         0.9939
  KBG                        539.1 ± 42.8   457.7 ± 41.0   0.0312\*                      
  FPG (mg/dL)                Control        101.4 ± 2.6    98.8 ± 2.5     0.0881         0.6065
  KBG                        97.6 ± 2.9     96.1 ± 2.7     0.1706                        
  IRI (*μ*U/mL)              Control        5.51 ± 0.63    5.12 ± 0.59    0.1525         0.2374
  KBG                        4.53 ± 0.50    4.76 ± 0.44    0.6260                        
  HOMA-IR                    Control        1.42 ± 0.19    1.28 ± 0.17    0.1342         0.2206
  KBG                        1.12 ± 0.14    1.15 ± 0.12    0.8140                        
  Creatinine (mg/dL)         Control        0.71 ± 0.03    0.70 ± 0.03    1.0000         0.4789
  KBG                        0.74 ± 0.04    0.75 ± 0.04    0.7539                        
  hs-CRP (mg/dL)             Control        0.16 ± 0.07    0.09 ± 0.04    0.4895         0.4382
  KBG                        0.17 ± 0.10    0.16 ± 0.07    0.8877                        
  MDA (nmol/mL)              Control        13.1 ± 2.8     12.8 ± 3.3     0.6747         0.0464\*
  KBG                        13.7 ± 1.7     10.5 ± 1.4     \<0.0001\*\*                  
  sVCAM-1 (ng/mL)            Control        710.1 ± 50.7   716.9 ± 56.4   0.4684         0.3898
  KBG                        666.1 ± 36.3   640.3 ± 41.4   0.3021                        

KBG: keishibukuryogan; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; L_RHI: natural logarithmic scaled reactive hyperemia; TG: triglyceride; HDL: high-density lipoprotein; LDL: low-density lipoprotein; NEFA, nonesterified fatty acid; FPG: fasting plasma glucose; IRI: immunoreactive insulin; HOMA-IR: homeostasis model assessment as an index of insulin resistance; hs-CRP: high-sensitive C-reactive protein; MDA: malondialdehyde; sVCAM-1: soluble vascular cell adhesion molecule 1.

^a^Comparison between week 0 and week 4 by Wilcoxon matched-pairs signed-ranks test.

^b^Comparison of 4-week changes between control period and KBG-treatment period by MANOVA test.

Data are expressed as mean ± S.E., \**P* \< 0.05, \*\**P* \< 0.01.

[^1]: Academic Editor: Ka Kit Hui
